Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) Overview
Learn About Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Florida Hospital Medical Group Inc
Jawad Francis is an Oncologist in Orlando, Florida. Dr. Francis and is rated as a Distinguished provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Breast Cancer, Hodgkin Lymphoma, and Small Cell Lung Cancer (SCLC). Dr. Francis is currently accepting new patients.
Florida Hospital Medical Group Inc
Tarek Mekhail is a Hematologist Oncology specialist and a Hematologist in Orlando, Florida. Dr. Mekhail and is rated as an Advanced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Mekhail is currently accepting new patients.
Thomas J Katta MD PA
Thomas Katta is a Hematologist Oncology specialist and a Hematologist in Orlando, Florida. Dr. Katta and is rated as an Experienced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Pleuropulmonary Blastoma, Anemia, Paris-Trousseau Thrombocytopenia, and RUNX1 Familial Platelet Disorder. Dr. Katta is currently accepting new patients.
Summary: This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cel...
Objective: * To develop the data collection infrastructure required to prospectively collect longitudinal electronic patient-reported outcomes (PROs) survey instruments in adult and pediatric patients diagnosed with NLPHL. Secondary Objective: * To examine differences in baseline and longitudinal changes in PROs based on disease characteristics, disease status, and treatment strategies among adult and pediat...